GENFIT outlines $1.5bn US peak-sales opportunity for MASH diagnostics platform

GENFIT says its MASH diagnostics technology could support more than $1.5 billion in peak US sales by 2033 as the market for non-invasive patient identification expands.

The company cited an IQVIA assessment of the commercial opportunity for products based on its NIS diagnostic technology as new MASH treatments increase demand for scalable non-invasive testing.

The forecast highlights the growing strategic value of diagnostics capable of identifying, stratifying and monitoring patients as the therapeutic MASH market develops.

Field	Content
Alert Type	Diagnostics commercialisation update
Company	GENFIT
Technology	NIS diagnostics technology
Therapy Area(s)	Metabolic dysfunction-associated steatohepatitis (MASH)
Geography	United States
Commercial Estimate	More than $1.5 billion in potential peak sales
Target Year	2033
Assessment Source	IQVIA
What Happened	GENFIT highlighted an IQVIA estimate indicating that products based on its NIS technology could generate more than $1.5 billion in peak US sales by 2033.
Why It Matters	The estimate underlines the expanding role of non-invasive diagnostics as pharmaceutical treatment options for MASH increase.
Supporting Context	MASH patient identification and monitoring remain important commercial and clinical challenges as new therapies enter the market.
Key Takeaway	GENFIT sees a substantial long-term commercial opportunity for its diagnostics platform alongside growth in the MASH therapeutics market.
What to Watch	Commercial partnerships, regulatory progress and adoption of NIS-based diagnostics alongside new MASH therapies.
Primary Source	GENFIT
Relevant Date	9 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com